Overview
October 3, 2009
Washington, DC
RECENT ADVANCES IN THE TREATMENT OF LUNG CANCER, AND HEAD& NECK CANCER
Program Director:
Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Hershey Cancer Institute, Hershey, PA
October 3, 2009 – Washington Marriott Hotel, 1221, 22nd Street NW, Washington, DC 20037 Phone: 1-202-872-1500
Jointly Sponsored by International Lung Cancer Network and Postgraduate Institute for Medicine
This activity is supported by educational grants from Bristol-Myers Squibb/Imclone Systems and Genentech BioOncology
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists, pharmacists, registered nurses, physician assistants, nurse practitioners interested in new developments for treatment of lung cancer, head & neck cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.
Statement of Need/Program Overview
This program is intended to facilitate interaction among oncologists, nurses, pharmacists, physician assistants, and nurse practitioners interested in the development of novel therapeutics for treatment of lung cancer, and head & neck cancer. This symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer, and head & neck cancer. There will be in-depth discussion of targeted therapies for lung cancer, and head & neck cancer.
Educational Objectives
After completing this activity, the participant should be better able to:
- Review agents that target angiogenesis, including the safety profile and efficacy for the treatment of lung cancer
- Review the current status of multimodality therapy for head & neck cancer
- Outline the clinical data supporting the use of EGFR inhibitors in the treatment of lung cancer
- Describe the role of systemic therapies for the treatment of head & neck cancer
- Specify the impact of multi-targeted kinase inhibitors in the management of lung cancer
- Describe the role of proteasome inhibitors, HDAC inhibitors and novel taxanes in treatment of lung cancer
- Describe novel therapeutic agents of interest for lung cancer and head & neck cancer
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Lung Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Accreditation Statements
purpose
The purpose of this educational meeting is to assist healthcare providers develop appropriate treatment strategies that minimize side effects and optimize outcomes in patients with lung cancer.
Accreditation Statements
ANCC
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
Credit Designation
This educational activity for 4.5 contact hours is provided by Postgraduate Institute for Medicine.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks (if applicable).
Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 809-999-09-094-L01-P)
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at 412-491-7492.